cart (0)
Recently added item(s)

View Cart

  • thumbnail Apple Pharmaceuticals thumbnail

Velasof

HepatitisC-Hetero-Velpatasvir-100mg-Sofosbuvir-400mg-Velasof

Availability: In stock

Special Price $ 290

Velasof DESCRIPTION

What is Velasof? Velasof (Generic Epclusa) is a generic antiviral drug produced by Hetero. It is used to treat chronic hepatitis C in adults. Velasof contains the active substances sofosbuvir and velpatasvir. How is Velasof used? Velasof medicine can only used to obtain with a prescription and treatment should be initiated and supervised by an experienced physician in the management of patients with chronic hepatitis C. Velasof stops multiplication of hepatitis C virus infection... Read Below

What is Velasof?

Velasof (Generic Epclusa) is a generic antiviral drug produced by Hetero.
It is used to treat chronic hepatitis C in adults.
Velasof contains the active substances sofosbuvir and velpatasvir.

How is Velasof used?

Velasof medicine can only used to obtain with a prescription and treatment should be initiated and supervised by an experienced physician in the management of patients with chronic hepatitis C. Velasof stops multiplication of hepatitis C virus infection of new cells.

Composition

Velasof is available as tablets containing of sofosbuvir 400mg and Velpatasvir 100mg. Hepatitis C virus exists in several varieties (genotypes), and Velasof can be used to treat hepatitis C caused by all genotypes of the virus.

In patients with decompensated liver disease (when the liver is no longer functioning properly), Velasof is taken together with another medicine, called ribavirin. Addition of ribavirin to Velasof treatment may also be considered in patients with compensated liver cirrhosis (liver sclerosis but with proper functioning) and who are infected with hepatitis C virus genotype 3, which is harder to treat.

Mechanism of Action

Velasof active substances, sofosbuvir 400mg and Velpatasvir 100mg, blocking two proteins essential for replication of hepatitis C virus sofosbuvir block the action of an enzyme called "NS5B RNA-dependent RNA polymerase" and velpatasvir targets a protein called "NS5A".
The recommended dose is one tablet taken once a day for 12 weeks.

The product summary and the package leaflet included recommendations and precautions for the safe and effective use of Velasof, to be followed by healthcare professionals and patients.